Cover Image
市場調查報告書

Linezolid的中國市場

Investigation Report on China Linezolid Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 332302
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Linezolid的中國市場 Investigation Report on China Linezolid Market, 2010-2019
出版日期: 2015年06月04日 內容資訊: 英文 20 Pages
簡介

Linezolid,是由Pharmacia & Upjohn所開發的合成Oxazolidinone化合物。在2000年取得FDA認證的Linezolid之同年銷售量為1億5000萬美元,但從2013年到2014年期間卻達到了13億5000萬美元。近幾年中國市場中Linezolid的銷售量非常不穩定,2014年的銷售量為9300萬人民幣,低於2010年當時記錄的銷售量 (1億1300萬人民幣) 。

本報告提供中國的Linezolid市場規模與今後預測,提供您主要製藥公司及劑型別市場佔有率,銷售價格等資訊。

第1章 Linezolid的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國Linezolid的市場簡介

  • Linezolid的專利及核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國Linezolid銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國Linezolid的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國Linezolid的劑型的相關調查

  • 劑型別市場佔有率:以銷售額為準
  • 劑型別市場佔有率:以銷售量為準

第6章 中國醫院的Linezolid的標準價格

  • Fresenius Kabi
  • Pfizer Inc. (美國)

第7章 中國市場中Linezolid的主要製藥公司

  • Pfizer Inc. (美國)
  • Fresenius Kabi
  • Pharmacia & Upjohn

第8章 中國Linezolid的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1506194

Infection caused by bacteria that are resistant to antibiotics is spreading over the world with increasing infection rate and mortality rate, which has posed a serious threat to human health. In 2004, National Nosocomial Infection Surveillance reported that people infected by Methicillin Resistant Staphylococcus Aureus (MRSA) take up 63.3% of all patients with nosocomial infection of staphylococcus aureus. Among staphylococcus aureus infections, MRSA separation rate occupied 69.2%. The mortality rate of MRSA infection is 20 times of Methicillin Sensitive Staphylococcus Aureus (MSSA).

Linezolid, a synthetic oxazolidinone, was developed by Pharmacia & Upjohn. In 2000, it was approved by FDA to be used for infection caused by gram-positive coccus, including suspected or confirmed Hospital Acquired Pneumonia (HAP) caused by MRSA, Community Acquired Pneumonia (CAP), skin and soft tissue infections (SSTI) and vancomycin-resistant enterococcus infection. Linezolid brought in sales revenue of USD 150 million in the same year it entered market and its sales in the global market during the period of 2013-2014 reached up to USD 1350 million. In China, linezolid market has long been monopolized by foreign pharmaceutical corporations. Since the patent for linezolid's crystal form shall expire in 2021, its price stays high.

Linezolid develops fast after entering China. In recent years, its sales value in the Chinese market has been extremely unstable, falling from CNY 113 million in 2010 to CNY 93 million in 2014. Currently, linezolid in the Chinese market comes from the following three companies: Pfizer Inc., Fresenius Kabi and Pharmacia & Upjohn, among which Pfizer has the largest market share of 69.92% with sales in 2014 reaching up to CNY 64.24 million.

Generally speaking, linezolid enjoys a vast demand in China.

Readers can get at least the following information through this report:

  • market size of linezolid in China
  • major manufacturers of linezolid in the Chinese market and their market share
  • retail price of linezolid in China
  • market outlook of linezolid in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-infectious agents
  • investors/ research institutions interested in Chinese medicine market
  • any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Linezolid

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Linezolid in China

  • 2.1. Patent and Approval Status of Linezolid in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Linezolid in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Linezolid in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Linezolid in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Linezolid in Chinese Hospitals in 2014

  • 6.1. Fresenius Kabi
  • 6.2. Pfizer Inc. (the US)

7. Major Manufacturers of Linezolid in Chinese Market, 2010-2014

  • 7.1. Pfizer Inc. (the US)
  • 7.2. Fresenius Kabi
  • 7.3. Pharmacia & Upjohn

8. Market Outlook of Linezolid in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Linezolid in China
  • Chart Approval Information of Linezolid in China
  • Chart Sales Status of Linezolid in Chinese Market, 2010-2014
  • Chart Sales Value of Linezolid in China, 2010-2014
  • Chart Sales Value of Linezolid in Some Regions in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Linezolid for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Linezolid Made by Pfizer (the US) in China, 2010-2014
  • Chart Sales Value and Market Share of Linezolid Made by Fresenius Kabi (NO) in China, 2010-2014
  • Chart Sales Value and Market Share of Linezolid Injections in China, 2010-2014
  • Chart Sales Value and Market Share of Linezolid Tablets in China, 2010-2014
  • Chart Price of Linezolid Made by Fresenius Kabi in Some Chinese Cities in 2014
  • Chart Price of Linezolid Made by Pfizer Inc. (the US) in Some Chinese Cities in 2014
Back to Top